Effects of Cilostazol on VEGF and Oxidative Stress Biomarkers in Hemodialysis Patients With Peripheral Vascular Disease
PHASE4CompletedINTERVENTIONAL
Enrollment
40
Participants
Timeline
Start Date
February 28, 2007
Primary Completion Date
April 30, 2008
Study Completion Date
April 30, 2008
Conditions
Hemodialysis PatientsPeripheral Vascular Disease
Interventions
DRUG
Cilostazol
All Listed Sponsors
lead
Tungs' Taichung Metroharbour Hospital
OTHER
NCT00431249 - Effects of Cilostazol on VEGF and Oxidative Stress Biomarkers in Hemodialysis Patients With Peripheral Vascular Disease | Biotech Hunter | Biotech Hunter